Next AdvaMed Chief Is BIO Exec Scott Whitaker
This article was originally published in The Gray Sheet
Whitaker, appointed as the next CEO of AdvaMed, currently runs day-to-day operations at the Biotechnology Innovation Organization and has held high-level posts at HHS. Among his accomplishments, Whitaker led the legislative office at HHS when the first device user fee bill was passed in 2002.
You may also be interested in...
AdvaMed's board just selected Scott Whitaker, a top executive at the Biotechnology Innovation Organization, as the trade group's next CEO. Before he starts in the new role on April 4, he spoke with The Gray Sheet about his vision.
The agency and industry agreed to create working groups allowing subject-matter experts to delve deeper into technical details on some of the key proposals raised thus far in user-fee reauthorization talks. Areas of focus include de novo reviews, pre-submissions and personnel recruitment challenges.
Multiple bills focused on accelerating the path to market for devices will join safety legislation reforming the regulation of duodenoscopes in a slate of Senate bills that HELP Committee Chairman Lamar Alexander said will receive hearings in February, March and April. The legislation-by-legislation approach in the Senate differs from the broad-based 21st Century Cures package that advanced in the House.